SCHEMBL3745697

SCHEMBL3745697

CN(CCN1CCOCC1)C(=O)c1cc2c(cn1)ncn2-c1cc(OCc2ccccc2C(F)(F)F)c(C(N)=O)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.60
NEK2 P51955 5/20 0.60
PLK3 Q9H4B4 4/20 0.60
CSF1R P07333 3/20 0.60
KDR P35968 3/20 0.60
LIMK1 P53667 3/20 0.60
STK3 Q13188 3/20 0.60
DYRK1A Q13627 3/20 0.60
BRSK1 Q8TDC3 3/20 0.60
CLK4 Q9HAZ1 3/20 0.60
MAP4K5 Q9Y4K4 3/20 0.60
SLK Q9H2G2 3/20 0.60
MAP4K4 O95819 2/20 0.60
PLK4 O00444 2/20 0.60
AURKA O14965 2/20 0.60
JAK2 O60674 2/20 0.60
LCK P06239 2/20 0.60
FGFR1 P11362 2/20 0.60
SRC P12931 2/20 0.60
FLT1 P17948 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3729503 0.87 PLK1 (0.61) PLK1NEK2PLK3CSF1RKDR
SCHEMBL5062032 0.82 PLK1 (0.73) PLK1NEK2PLK3CSF1RKDR
SCHEMBL4041060 0.82 PLK1 (0.78) PLK1NEK2PLK3CSF1RKDR
SCHEMBL5067369 0.82 PLK1 (0.78) PLK1NEK2PLK3CSF1RKDR
SCHEMBL5063376 0.81 PLK1 (0.67) PLK1NEK2PLK3CSF1RKDR
SCHEMBL3737267 0.81 IKBKE (0.55) PLK1NEK2PLK3CSF1RKDR
SCHEMBL3933141 0.80 PLK1 (0.78) PLK1NEK2PLK3CSF1RKDR
SCHEMBL3734876 0.79 NEK2 (0.68) PLK1NEK2PLK3CSF1RKDR
SCHEMBL4034885 0.78 PLK1 (0.64) PLK1NEK2PLK3CSF1RKDR
SCHEMBL3736522 0.78 PLK1 (0.80) PLK1NEK2PLK3CSF1RKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100278833-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2010-11-04 US claimed
EP-2017277-A1 Thiophene-imidazopyridines 4SC AG (DE) 2009-01-21 EP claimed
WO-2009003911-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2009-01-08 WO claimed
US-8273890-B2 Thiophene-imidazopyridines 4SC AG (DE) 2012-09-25 US disclosed
US-20100278833-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2010-11-04 US disclosed
EP-2017277-A1 Thiophene-imidazopyridines 4SC AG (DE) 2009-01-21 EP disclosed
WO-2009003911-A1 THIOPHENE-IMIDAZOPYRIDINES 4SC AG (DE) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100278833-A1 THIOPHENE-IMIDAZOPYRIDINES PIKFYVE, PIP4K2B, PIP5K1B PLK1 642/4885NEK2 2328/4885PLK3 1528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.